NASDAQ: INVA · Biotechnology
Innoviva (INVA) fair value and price range
As of 14 Nov 2026, Faircurve's model values Innoviva (INVA) at $19.11 a share. The stock last closed at $18.49, which puts the model's fair value 3.4% above the price. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
Revalued . Price is the close of 16 Nov 2026. Innoviva, Inc.
The report adds the live price, the price chart, the next earnings date and the analysts' consensus. No account needed.
This week, in three parts
What happenedThe run of 14 Nov 2026 held the fair value at $19.11, within 1% of the run of 7 Nov 2026.
What the model makes of itThe price of $18.49 is 3.4% below it. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
What's nextNext report on 24 Feb 2027. The next weekly run is on Saturday 21 Nov 2026.
What price range does the model give INVA?
The calibrated range for INVA over 63 trading days is $15.28 to $22.70. There is no live options data for this stock, so the range is built from the fair value and calibrated weekly against realised prices (n = 13,250 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $13.85 to $26.83. In 50% of the simulations the fair value came out above the price the model ran on.
Faircurve Insights · 14 Nov 2026
Innoviva, Inc. (INVA) sits in Healthcare and Biotechnology. It functions as a pharmaceutical company, concentrating on the worldwide creation and marketing of medical treatments.
Faircurve's model put the fair value of Innoviva at $19.11 a share on 14 Nov 2026, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $19.18, so the fair value moved -0.4%. The calibrated range over 63 trading days is $15.28 to $22.70. It is built from the fair value, as there is no live options data for the stock. The range is calibrated weekly against realised prices, using 13,250 past valuations, refreshed 14 Nov 2026. Ranges built this way held the price 60% of the time at this horizon. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at the completeness of the inputs, the number of comparable companies and how closely they agree, and the width of the range. It does not say whether the fair value is right.
Faircurve's model compares Innoviva with three companies, each with a fair value of its own on the site: Fortrea Holdings Inc. (FTRE), Vericel Corporation (VCEL) and ADMA Biologics, Inc. (ADMA). Five further comparable companies have no verdict on this date: Vir Biotechnology, Inc. (VIR), Sarepta Therapeutics, Inc. (SRPT), Harmony Biosciences Holdings, Inc. (HRMY), Arcus Biosciences, Inc. (RCUS) and Xencor, Inc. (XNCR). This note gives no quality score or factor measure for the business.
Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does INVA report earnings, and how has the stock reacted?
Innoviva's next earnings report is scheduled for 24 Feb 2027. Companies can move their dates.
Around its last 8 reports: what the options market priced, and what followed
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across INVA's last 8 reports, ignoring direction, was 1.9%.
How does INVA compare with similar companies?
The companies in biotechnology closest to Innoviva in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| VIR Vir Biotechnology, Inc. | $9.58 | $9.51 | -0.7% | Low evidence grade |
| SRPT Sarepta Therapeutics, Inc. | $15.13 | $19.51 | +28.9% | Low evidence grade |
| FTRE Fortrea Holdings Inc. | $19.79 | $24.79 | +25.3% | Undervalued |
| HRMY Harmony Biosciences Holdings, Inc. | $32.96 | $33.93 | +2.9% | Low evidence grade |
| RCUS Arcus Biosciences, Inc. | $16.86 | $16.32 | -3.2% | Low evidence grade |
| XNCR Xencor, Inc. | $35.40 | $35.72 | +0.9% | Low evidence grade |
| VCEL Vericel Corporation | $57.48 | $65.96 | +14.8% | Fairly valued |
| ADMA ADMA Biologics, Inc. | $13.47 | $15.96 | +18.5% | Undervalued |
Innoviva at a glance
Innoviva, Inc. functions as a pharmaceutical company, concentrating on the worldwide creation and marketing of medical treatments.
- Market value
- $1.4B
- Sector
- Healthcare
- Industry
- Biotechnology
- Revenue expected, next twelve months
- $471M
- Consensus revenue growth, next fiscal year
- +3.0%
- Analysts with estimates
- 3
- Beta to the US market
- 0.21
- First valued by Faircurve
- 11 Jul 2026
How the fair value is worked out: the model prices Innoviva on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 7 Nov 2026 the model's fair value for INVA was $19.18. As of 14 Nov 2026 it is $19.11, a change of -0.4%. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Innoviva's valuation
Is Innoviva stock undervalued or overvalued?
Faircurve's model puts INVA's fair value at $19.11 a share against a last close of $18.49, as of 14 Nov 2026. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
What is INVA's fair value?
$19.11 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $13.85 to $26.83.
What price range does the model give INVA?
$15.28 to $22.70 over 63 trading days. Ranges built this way held the price 60% of the time across 13,250 past valuations, refreshed 14 Nov 2026.
When does Innoviva report earnings next?
The next report is scheduled for 24 Feb 2027. Companies can move their dates.
How much has INVA moved on past earnings reports?
Across its last 8 reports the median two session move was 1.9%, ignoring direction. The largest was +13.4% around the report of 5 Nov 2025.
How confident is the model in this valuation?
The model's evidence grade for INVA is low. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.
The model's own ideas on INVA
The model holds no idea open on INVA today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on INVA with their outcomes. A free account is enough.